ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA reported that Chief Legal Officer Peter J. Graham received a grant of 294,800 Common Shares on February 13, 2026, valued at $3.99 per share. These shares relate to a restricted share unit award that vests in three equal annual installments beginning on the first anniversary of the grant date, subject to continued service.
The company also withheld 33,294 Common Shares at $3.99 per share to cover Mr. Graham’s tax obligations upon vesting of previously granted restricted share units, which is a non‑market tax-withholding disposition rather than an open-market sale. Following these transactions, Mr. Graham directly holds 620,540 Common Shares.
ADC Therapeutics SA Chief Financial Officer Jose Carmona reported equity-related transactions in company common shares. He was granted 271,600 common shares at $3.99 per share as part of a restricted share unit award that vests in three equal annual installments starting on February 13, 2027, contingent on continued service. To cover tax withholding from the vesting of previously granted restricted share units, 25,880 common shares were withheld by the company at $3.99 per share. After these transactions, Carmona directly holds 734,376 common shares.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik acquired 900,000 Common Shares on February 13, 2026 as part of a restricted share unit award valued at $3.99 per share. According to a footnote, these shares will be delivered over time as the RSUs vest: one-third on the first anniversary of the February 13, 2026 grant date and one-third on each of the next two anniversaries, subject to continued service.
On the same date, 103,231 Common Shares were disposed of through a tax-withholding transaction at $3.99 per share to cover Mr. Mallik’s tax obligations related to previously granted RSUs vesting. After these transactions, he directly held 1,446,769 Common Shares. A separate indirect holding of 669,101 Common Shares is reported as held by a grantor retained annuity trust, and Mr. Mallik disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.
ADC Therapeutics received an amended Schedule 13G showing updated ownership by OrbiMed investment entities as of 12/31/2025. OrbiMed Advisors LLC reports beneficial ownership of 2,592,057 common shares, representing 2.1% of the class, with shared voting and dispositive power over these shares.
OrbiMed Capital LLC reports beneficial ownership of 3,230,797 common shares, representing 2.6% of the class, with sole voting and dispositive power. Together, the reporting persons hold an aggregate 4.7% of ADC Therapeutics’ common shares on behalf of other persons entitled to dividends or sale proceeds. They certify the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
ADC Therapeutics SA received an updated ownership report showing that investment entities affiliated with Point72, including Point72 Asset Management, Point72 Capital Advisors and Steven A. Cohen, beneficially owned 5,014,617 common shares, representing 4.0% of the company’s common shares as of December 31, 2025.
The filing states these entities have shared voting and dispositive power over all reported shares, held through an investment fund managed by Point72 Asset Management. The reporting persons certify the shares were not acquired or held to change or influence control of ADC Therapeutics.
ADC Therapeutics SA received a Schedule 13G from TCG Crossover Fund II and related parties reporting a significant passive stake. The reporting persons collectively beneficially own 11,390,175 common shares, representing 9.2% of the outstanding common shares.
The shares are held of record by TCG Crossover Fund II, with TCG Crossover GP II as general partner and Chen Yu as sole managing member, giving them shared voting and dispositive power. The ownership percentage is based on 123,877,111 common shares outstanding as of October 31, 2025. The filers certify the holdings are not for the purpose of changing or influencing control of ADC Therapeutics.
Redmile Group and affiliates report a significant passive stake in ADC Therapeutics. Redmile Group, Jeremy C. Green and RedCo II Master Fund jointly report beneficial ownership of 15,666,731 common shares, representing 12.7% of ADC Therapeutics’ common stock, based on 123,877,111 shares outstanding as of October 31, 2025.
Within this, RedCo II Master Fund, L.P. is attributed 13,145,712 shares, or 10.6% of the class. The group also holds pre-funded warrants that could deliver up to 27,743,685 additional shares for certain Redmile clients, including 22,445,224 for RedCo II, but these are blocked from exercise above a 9.99% ownership threshold.
The filers certify the securities were not acquired and are not held to change or influence control of ADC Therapeutics, indicating a passive investment intent under Schedule 13G/A.
ADC Therapeutics SA received an amended Schedule 13G showing that investment entities affiliated with Prosight report beneficial ownership of 8,477,338 common shares, representing 6.8% of the company’s outstanding stock. All of these shares are held with shared voting and shared dispositive power.
The ownership is spread across Prosight-managed vehicles, including Prosight Fund and Prosight Plus Fund, which directly hold common shares, and certain managed accounts. The filing is certified as a passive investment, stating the securities were not acquired to change or influence control of ADC Therapeutics.
ADC Therapeutics SA released an updated corporate presentation and furnished it as an exhibit to a current report. The presentation is attached as Exhibit 99.1 and is meant to provide investors and other stakeholders with more detail about the company and its activities. The company notes that this material is being furnished under Regulation FD, which is designed to ensure fair disclosure of information. The presentation and related information are not treated as formally filed financial statements and are not automatically incorporated into other securities law filings unless specifically referenced.
ADC Therapeutics SA reported that it has released preliminary estimates for its revenue for the quarter and year ended December 31, 2025, along with preliminary cash and cash equivalents as of that date. These figures were disclosed in a press release dated January 8, 2026, which is attached as an exhibit.
The company emphasized that these revenue and cash numbers are preliminary, unaudited and based on management’s complex judgments and estimates. Actual results for the quarter and full year 2025 are not yet finalized or reviewed by independent auditors and may differ materially from these early estimates. The information is being furnished for disclosure purposes and is not deemed filed under the securities laws unless specifically incorporated by reference.